Page 47 - Read Online
P. 47

Kwee et al. Hepatoma Res 2021;7:8  I  http://dx.doi.org/10.20517/2394-5079.2020.124                                           Page 13 of 13

               63.  Boyault S, Rickman DS, de Reyniès A, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic
                   targets. Hepatology 2007;45:42-52.
               64.  Chiang DY, Villanueva A, Hoshida Y, et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res
                   2008;68:6779-88.
               65.  Huang X, Yang C, Wang J, Sun T, Xiong H. Integrative analysis of DNA methylation and gene expression reveals distinct hepatocellular
                   carcinoma subtypes with therapeutic implications. Aging (Albany NY) 2020;12:4970-95.
               66.  Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res
                   2017;77:e108-10.
               67.  Tan PS, Nakagawa S, Goossens N, et al. Clinicopathological indices to predict hepatocellular carcinoma molecular classification. Liver
                   Int 2016;36:108-18.
               68.  Qiu J, Xu J, Zhang K, et al. Refining cancer management using integrated liquid biopsy. Theranostics 2020;10:2374-84.
               69.  Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.
                   Nat Protoc 2009;4:44-57.
               70.  Ramapriyan R, Caetano MS, Barsoumian HB, et al. Altered cancer metabolism in mechanisms of immunotherapy resistance. Pharmacol
                   Ther 2019;195:162-71.
               71.  Wei R, Wang J, Wang X, et al. Clinical prediction of HBV and HCV related hepatic fibrosis using machine learning. EBioMedicine
                   2018;35:124-32.
               72.  Wang T, Yang X, Tang H, et al. Integrated nomograms to predict overall survival and recurrence-free survival in patients with combined
                   hepatocellular cholangiocarcinoma (cHCC) after liver resection. Aging (Albany NY) 2020;12:15334-58.
               73.  Chen W, Samuelson FW, Gallas BD, Kang L, Sahiner B, Petrick N. On the assessment of the added value of new predictive biomarkers.
                   BMC Med Res Methodol 2013;13:98.
               74.  Cook NR. Quantifying the added value of new biomarkers: how and how not. Diagn Progn Res 2018;2:14.
               75.  Benson AB, D’Angelica MI, Abbott DE, et al. Guidelines insights: hepatobiliary cancers, Version 2.2019. J Natl Compr Canc Netw
                   2019;17:302-10.
   42   43   44   45   46   47   48   49   50   51   52